Committed Investment: May, 2020
Status: Active Portfolio Company
Stem Pharm (Madison) is a biotech company applying its expertise in stem cell biology and biomaterials to enable the next generation of therapeutics for neurologic diseases. Stem Pharm creates stem cell derived in vitro models of the central nervous system (i.e. “brains in a dish”) used by pharma partners for studying disease biology, discovering new drugs, and for precision medicine. These tools will enable breakthroughs for neurodegenerative diseases and brain cancers where very little progress has been made in the last two decades. In addition, the company’s tissue models will reduce the reliance on animal use in research.